Results 71 to 80 of about 415 (104)

Circulating immune and plasma biomarkers of time to HIV rebound in HIV controllers treated with vesatolimod. [PDF]

Front Immunol
Abdel-Mohsen M, Deeks S, Giron L, Hong KY, Goldman A, Zhang L, Huang SSY, Verrill D, Guo S, Selzer L, de Vries CR, Vendrame E, SenGupta D, Wallin JJ, Cai Y.   +14 more
europepmc   +1 more source

Femoral arteriovenous concentration differences reveal metabolomic shifts in peripheral artery disease (PAD): A case-control study. [PDF]

Vasc Med
Ööbik T, Kals J, Eha J, Zilmer M, Kilk K, Paapstel K.   +5 more
europepmc   +1 more source

Dysregulated metabolism of ceramides and glycosphingolipids in Parkinson's disease. [PDF]

J Lipid Res
Peng YF, Chen SJ, Li JL, Lin CH, Kuo CH.
europepmc   +1 more source

Profiles of Globotriaosylsphingosine Analogs and Globotriaosylceramide Isoforms Accumulated in Body Fluids from Various Phenotypic Fabry Patients. [PDF]

Intern Med
Shiga T, Tsukimura T, Kubota T, Togawa T, Sakuraba H.   +4 more
europepmc   +1 more source

Globotriaosylceramide Gb3 Influences Wound Healing and Scar Formation by Orchestrating Fibroblast Heterogeneity. [PDF]

Adv Sci (Weinh)
Xie S, Huang R, Qian W, Ding X, Zhang W, Li Y, Lu J, Sun H, Liu Y, Yao Y, Lu B, Wu M, Xia Z, Ji S.   +13 more
europepmc   +1 more source

Profile of serum lipid metabolites of one-week-old goat kids depending on the type of rearing. [PDF]

BMC Vet Res, 2020
Czopowicz M, Moroz A, Szaluś-Jordanow O, Mickiewicz M, Witkowski L, Nalbert T, Markowska-Daniel I, Puchała R, Bagnicka E, Kaba J.   +9 more
europepmc   +1 more source

Lentivirus-mediated gene therapy for Fabry disease: 5-year End-of-Study results from the Canadian FACTs trial. [PDF]

Clin Transl Med
Khan A, Barber DL, McKillop WM, Rupar CA, Auray-Blais C, Fraser G, Fowler DH, Berger A, Foley R, Keating A, West ML, Medin JA.   +11 more
europepmc   +1 more source

Computational Enzymology, a ReaxFF approach [PDF]

, 2013
Corozzi, Alessandro
core  

Long-Term Clinical-Pathologic Results of Enzyme Replacement Therapy in Prehypertrophic Fabry Disease Cardiomyopathy. [PDF]

J Am Heart Assoc
Frustaci A, Verardo R, Galea N, Alfarano M, Magnocavallo M, Marchitelli L, Sansone L, Belli M, Cristina M, Frustaci E, Russo MA, Chimenti C.   +11 more
europepmc   +1 more source

Progress and Challenges in the Treatment of Fabry Disease. [PDF]

BioDrugs
Lenders M, Menke ER, Brand E.
europepmc   +1 more source